ARTICLE | Product Development
Grail partnership latest step for broader access to multicancer tests
Study to evaluate community outreach strategies for increasing early cancer screening in diverse populations, follows similar deal by Exact Sciences in June
August 25, 2023 7:09 PM UTC
With real-world data becoming key for understanding the clinical utility of multicancer early detection (MCED) tests, evaluating the blood tests in diverse populations and care settings is critical. Non-profit partnerships announced this half by Grail and Exact Sciences aim to build that understanding by bringing the companies’ tests to underserved populations.
In the absence of FDA approval and widespread reimbursement, real-world use of the cell-free DNA (cfDNA)-based Galleri MCED test from the Grail LLC unit of Illumina Inc. (NASDAQ:ILMN), which is marketed via the laboratory-developed test (LDT) pathway, is primarily limited to those who can afford the $949 price tag. ...